NAT2 and chronic myelogenous leukemia, BCR-ABL1 positive: NAT2 590AG was higher in the healthy control (67%) than CML patients (59%), but again, with OR = 0.687, 95% CI:0.389-1.211 and p = 0.194, this difference was not significant.